EP2749283A3 — Combination of glycopyrronium and olodaterol
Assigned to Cipla Ltd · Expires 2014-08-20 · 12y expired
What this patent protects
The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrronium in combination with olodaterol, and optionally fluticasone or mometasone; to a process for preparing such compositions and to the use of such compositions for the prevention and/…
USPTO Abstract
The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrronium in combination with olodaterol, and optionally fluticasone or mometasone; to a process for preparing such compositions and to the use of such compositions for the prevention and/or treatment of respiratory, inflammatory or obstructive airway disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.